Enhancing Minority and Women Representation in NIH Medical Research Act of 2016
A BILL
To amend the Public Health Service Act to promote the inclusion of minorities and women in clinical research, and for other purposes.
Sec. 2 Collaboration to enhance diversity in clinical research
“(4) shall assemble accurate data to be used to assess research priorities, including—
“(A) information to better evaluate scientific opportunity, public health burdens, and progress in reducing health disparities; and
“(B) data on study populations of clinical research, funded by or conducted at each national research institute and national center, which—
“(i) specifies the inclusion of—
“(I) women;
“(II) members of minority groups;
“(III) relevant age categories; and
“(IV) other demographic variables determined to be necessary by the Director of NIH;
“(ii) is disaggregated by research area, condition, and disease categories; and
“(iii) is to be made publicly available on the Internet website of the National Institutes of Health;”
“(C) foster collaboration between clinical research projects funded by the respective national research institutes and national centers that—
“(i) conduct research involving human subjects; and
“(ii) collect similar data; and
“(D) encourage the collaboration described in subparagraph (C) to—
“(i) allow for an increase in the number of subjects studied; and
“(ii) utilize diverse study populations, with special consideration to biological, social, and other determinants of health that contribute to health disparities;”
Sec. 3 Promoting inclusion in clinical research
“(3) Strategic planning
“(A) In general—The directors of the national institutes and national centers shall consult at least once annually with the Director of the National Institute on Minority Health and Health Disparities and the Director of the Office of Research on Women’s Health regarding objectives of the national institutes and national centers to ensure that future activities by such institutes and centers take into account women and minorities and are focused on reducing health disparities.
“(B) Strategic plans—Any strategic plan issued by a national institute or national center shall include details on the objectives described in subparagraph (A).”
“(1) In general—In the case”
“(2) Reporting requirements—For any new and competing project of clinical research subject to the requirements under this section that receives a grant award 1 year after the date of enactment of the Enhancing Minority and Women Representation in NIH Medical Research Act of 2016, or any date thereafter, for which a valid analysis is provided under paragraph (1)—
“(A) and which is an applicable clinical trial as defined in section 402(j), the entity conducting such clinical research shall submit the results of such valid analysis to the clinical trial registry data bank expanded under 402(j)(3), and the Director of NIH shall, as appropriate, consider whether such entity has complied with the reporting requirement described in this subparagraph in awarding any future grant to such entity, including pursuant to section 402(j)(5)(A)(ii) when applicable; and
“(B) the Director of NIH shall encourage the reporting of the results of such valid analysis described in paragraph (1) through any additional means determined appropriate by the Director.”
“(1) In general—The advisory council”
“(2) Contents—Each triennial report prepared by an advisory council of each national research institute as described in paragraph (1) shall include each of the following:
“(A) The number of women included as subjects, and the proportion of subjects that are women, in any project of clinical research conducted during the applicable reporting period, disaggregated by categories of research area, condition, or disease, and accounting for single-sex studies.
“(B) The number of members of minority groups included as subjects, and the proportion of subjects that are members of minority groups, in any project of clinical research conducted during the applicable reporting period, disaggregated by categories of research area, condition, or disease and accounting for single-race and single-ethnicity studies.
“(C) For the applicable reporting period, the number of projects of clinical research that include women and members of minority groups and that—
“(i) have been completed during such reporting period; and
“(ii) are being carried out during such reporting period and have not been completed.
“(D) The number of studies completed during the applicable reporting period for which reporting has been submitted in accordance with subsection (c)(2)(A).”